Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables
Pharmaceutics · 19.04.2024 · 16 (4) · 552
DOI: 10.3390/pharmaceutics16040552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 19.04.2024. Verfasst von Daniela Amaral Silva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Simulations Plus, Incorporated, 42505 10th Street West, Lancaster, CA 93534, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Food and Drug Administration.
Abstract (Originalsprache)
Long-acting injectable (LAI) formulations provide sustained drug release over an extended period ranging from weeks to several months to improve efficacy, safety, and compliance. Nevertheless, many challenges arise in the development and regulatory assessment of LAI drug products due to a limited understanding of the tissue response to injected particles (e.g., inflammation) impacting in vivo performance. Mechanism-based in silico methods may support the understanding of LAI–physiology interactions. The objectives of this study were as follows: (1) to use a mechanistic modeling approach to delineate the in vivo performance of DepoSubQ Provera® and formulation variants in preclinical species; (2) to predict human exposure based on the knowledge gained from the animal model. The PBPK model evaluated different elements involved in LAI administration and showed that (1) the effective in vivo particle size is potentially larger than the measured in vitro particle size, which could be due to particle aggregation at the injection site, and (2) local inflammation is a key process at the injection site that results in a transient increase in depot volume. This work highlights how a mechanistic modeling approach can identify critical physiological events and product attributes that may affect the in vivo performance of LAIs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Simulations Plus, Incorporated, 42505 10th Street West, Lancaster, CA 93534, USA.
- Division of Quantitative Methods and Modeling, Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Sprin…
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA.
ORCID-Profile: Maxime Le Merdy, Quanying Bao, Diane Burgess
Förderung
- United States Food and Drug Administration
Zitieren
APA
Amaral Silva, D., Le Merdy, M., Alam, K. D., Wang, Y., Bao, Q., Malavia, N., Burgess, D., & Lukacova, V. (2024). Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables. Pharmaceutics, 16(4), 552. https://doi.org/10.3390/pharmaceutics16040552
Vancouver
Amaral Silva D, Le Merdy M, Alam KD, Wang Y, Bao Q, Malavia N, et al. Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables. Pharmaceutics. 2024;16(4):552. doi:10.3390/pharmaceutics16040552
BibTeX
@article{AmaralSilva2024,
author = {Amaral Silva, Daniela and Le Merdy, Maxime and Alam, Khondoker Dedarul and Wang, Yan and Bao, Quanying and Malavia, Nilesh and Burgess, Diane and Lukacova, Viera},
title = {Development of Mechanistic In Vitro–In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {4},
pages = {552},
doi = {10.3390/pharmaceutics16040552}
}
EUVIMED